Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
NCT07176390 · View on ClinicalTrials.gov ↗
Study Summary
Researchers are looking for new ways to treat rheumatoid arthritis (RA). Methotrexate (MTX) is a standard (usual) treatment for RA. However, MTX and other current treatments may not work well to treat RA symptoms for many people. This study will help find out if a study medicine called tulisokibart can treat symptoms of active RA in people who are taking MTX. In this study, researchers will look at different doses of tulisokibart. Researchers want to learn if at least one of the study doses of tulisokibart works better than a placebo to lessen RA symptoms. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of the study medicine.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Methotrexate
- DRUG Tulisokibart
Study Locations (20)
Texas
- Rheumatology Associates ( Site 1026) — Arlington
- Epic Medical Research ( Site 1004) — Red Oak
- Advanced Rheumatology of Houston - Woodlands ( Site 1000) — The Woodlands
Arizona
- Arizona Arthritis & Rheumatology Associates, P.C. ( Site 1018) — Glendale
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Mesa ( Site 1033) — Mesa
Florida
- Sweet Hope Research Specialty, Inc ( Site 1015) — Hialeah
- HMD Research LLC ( Site 1016) — Orlando
Pennsylvania
- altoona center for clinical research ( Site 1005) — Duncansville
- Rheumatology Specialty Center ( Site 1030) — Willow Grove
Quebec
- CIUSSS de l'Estrie - CHUS, Hotel-Dieu de Sherbrooke ( Site 1106) — Sherbrooke
- Centre de Recherche Musculo-Squelettique ( Site 1101) — Trois-Rivières
Region M. de Santiago
- Centro de Estudios GyC ( Site 1206) — Santiago
- Clinica Dermacross ( Site 1203) — Santiago
California
- Arthritis & Osteoporosis Medical Center - La Palma ( Site 1024) — La Palma
Colorado
- Tekton Research, LLC. ( Site 1008) — Fort Collins
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 182 participants |
| Start Date | 2025-10-08 |
| Est. Completion | 2029-09-03 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07176390
The ClinicalTrials.gov registry entry for NCT07176390 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 182 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 741 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Arthritis, Rheumatoid appearing as the primary indexed condition, and to 3 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07176390 reports 20 study locations spanning 13 distinct geographic areas — top geographies include Texas, Arizona, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07176390 about?
NCT07176390 is a clinical study titled "A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)". Researchers are looking for new ways to treat rheumatoid arthritis (RA). Methotrexate (MTX) is a standard (usual) treatment for RA. However, MTX and other current treatments may not work well to treat RA symptoms for many people. This study will help find out if a study medicine called tulisokibart...
What is the current status of trial NCT07176390?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 182 participants. The study started on 2025-10-08. Estimated completion is 2029-09-03.
What conditions does trial NCT07176390 study?
This clinical trial studies the following conditions: Arthritis, Rheumatoid. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07176390?
The interventions under investigation include: Placebo (DRUG), Methotrexate (DRUG), Tulisokibart (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07176390?
This trial is sponsored by Merck Sharp & Dohme, which has 741 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07176390 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.